Inhibition of the mevalonate pathway by simvastatin interferes with mast cell degranulation by disrupting the interaction between Rab27a and double C2 alpha proteins.

MLA

Sahid, Muhammad Novrizal Abdi, et al. “Inhibition of the Mevalonate Pathway by Simvastatin Interferes with Mast Cell Degranulation by Disrupting the Interaction between Rab27a and Double C2 Alpha Proteins.” European Journal of Pharmacology, vol. 814, Nov. 2017, pp. 255–63. EBSCOhost, https://doi.org/10.1016/j.ejphar.2017.08.026.

APA

Sahid, M. N. A., Liu, S., Kiyoi, T., & Maeyama, K. (2017). Inhibition of the mevalonate pathway by simvastatin interferes with mast cell degranulation by disrupting the interaction between Rab27a and double C2 alpha proteins. European Journal of Pharmacology, 814, 255–263. https://doi.org/10.1016/j.ejphar.2017.08.026

Chicago

Sahid, Muhammad Novrizal Abdi, Shuang Liu, Takeshi Kiyoi, and Kazutaka Maeyama. 2017. “Inhibition of the Mevalonate Pathway by Simvastatin Interferes with Mast Cell Degranulation by Disrupting the Interaction between Rab27a and Double C2 Alpha Proteins.” European Journal of Pharmacology 814 (November): 255–63. doi:10.1016/j.ejphar.2017.08.026.